Date: 2014-07-28
Type of information: Commercialisation agreement
Compound: Caphosol®
Company: CANbridge Life Sciences (China) EUSA Pharma, a division of Jazz Pharmaceuticals (Ireland)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: Caphosol® is a patented, oral electrolyte solution designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx. In the United States, Caphosol® is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the conditions are temporary or permanent. Caphosol® is also indicated as an adjunct to standard oral care in treating the mucositis that may be caused by radiation or high dose chemotherapy. In the European Union, Caphosol® is a Class I CE marked medical device indicated for dryness of the mouth and oropharynx (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent. Caphosol® is also indicated as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation or high dose chemotherapy.
Disease: oral mucositis
Details: * On July 28, 2014, CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize Caphosol® in China. Under the terms of the agreement, CANbridge obtains exclusive rights to commercialize Caphosol® in China, where over 3.5 million new cancer cases are diagnosed each year, and there is little in the way of a standard adjunct therapy to treat oral mucositis.
Financial terms:
Latest news:
